ClinicalTrials.gg
CompletedNCT02226198HYDRAUpdated Jul 4, 2016Results posted

A Study to Evaluate the Efficacy and Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial Hypercholesterolemia

A Phase 3 interventional study of Rosuvastatin 20mg and Placebo in Homozygous Familial Hypercholesterolemia (HoFH), sponsored by AstraZeneca. Completed at 9 sites in 7 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2016-07-04.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Study summary

The purpose of the study is to establish the efficacy, safety and tolerability of rosuvastatin in children and adolescents with homozygous familial hypercholesterolemia.

Read the detailed description

This is a randomized, double-blind, placebo-controlled, multi-center, cross-over study of the efficacy, safety and tolerability rosuvastatin in children and adolescents (aged 6 to \<18 years) with homozygous familial hypercholesterolemia (HoFH). The study is designed to assess the efficacy of rosuvastatin 20 mg compared to placebo on lipids, lipoproteins and apolipoproteins in pediatric patients with HoFH. The outcome measures to be assessed include low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), total cholesterol (TC), triglycerides, non-HDL-C, LDL-C/HDL-C, TC/HDL-C, non-HDL-C/HDL-C, apolipoprotein B (ApoB), apolipoprotein A 1 (ApoA-1) and ApoB/ApoA-1 following 6 weeks of treatment with rosuvastatin 20 mg or placebo. Pharmacokinetic data of the trough plasma exposure of rosuvastatin will also be assessed in these pediatric patients with HoFH.

02

Conditions studied

  • Homozygous Familial Hypercholesterolemia (HoFH)

Keywords

  • LDL-C
  • HoFH
  • Hyperlipidemia
03

In context

Homozygous Familial Hypercholesterolemia

68 studies on the registry are indexed under Homozygous Familial Hypercholesterolemia; 13 are open to participants now.

This study's enrollment of 20 is close to the median of 21 across 51 interventional studies indexed under Homozygous Familial Hypercholesterolemia.

Browse Homozygous Familial Hypercholesterolemia studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Prior to any study related procedures being performed, provision of written from a parent/both parents or guardian and statement of assent from the child or adolescent (if required by Institutional Review Board [IRB] or Independent Ethics Committee [EC] according to local regulations and guidelines). Communication between the Investigator, patient/guardian and child/adolescent to confirm understanding and required compliance with the requirements of the study.
  2. Male and female children and adolescents (aged 6 to \<18 years) with at least 1 of the following criteria:

    Documentation of genetic testing confirming 2 mutated alleles of the LDL receptor gene locus; and/or

    Documented untreated LDL C >500 mg/dL (12.9 mmol/L) and triglyceride (TG) \<300 mg/dL (3.4 mmol/L) and at least 1 of the following criteria:

    1. Tendinous and/or cutaneous xanthoma prior to 10 years of age; or
    2. Documentation of HoFH in both parents by:

      • genetic and/or
      • clinical criteria
  3. Negative pregnancy test (b human chorionic gonadotropin analysis) prior to baseline in females of child bearing potential:

    • Female patients of child bearing potential must adhere to a pregnancy prevention method (abstinence, chemical, or mechanical) during the study and 3 months following the last dose.
    • Male patients should refrain from fathering a child (including sperm donation) during the study and up to 3 months following the last dose; and
  4. Willing to follow all study procedures including adherence to dietary guidelines, study visits, fasting blood draws, and compliance with study treatment regimens.

Exclusion criteria

Exclusion Criteria

  1. History of statin inducted myopathy or serious reaction to other HMG CoA reductase inhibitors (statins), including rosuvastatin, at Visit 1.
  2. Fasting serum glucose of >9.99 mmol/L (180 mg/dL) or glycosylated >9% at Visit 1 or patients with a history of diabetic ketoacidosis within the past year.
  3. Uncontrolled hypothyroidism defined as thyroid stimulating hormone (TSH) >1.5 times the (ULN) at Visit 1 or patients whose thyroid replacement therapy was initiated or modified within the last 3 months prior to Visit 2.
  4. Current active liver disease or hepatic dysfunction (except a confirmed diagnosis of Gilbert's disease) as defined as elevations of 1.5 times the upper limit of normal (ULN) for any age in any of the following liver function tests at Visit 1: (ALT), Aspartate Aminotransferase (AST), or .
  5. Definite or suspected personal history or family history of adverse drug reactions (ADRs), or hypersensitivity to drugs with a similar chemical structure to rosuvastatin as well as other statins.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
20 participants (actual)

Study arms

  • Active comparator
    Rosuvastatin

    6-week treatment period, and after crossover finished a 12-week efficacy maintenance phase for all patients

    Drug: Rosuvastatin 20mg

  • Placebo comparator
    Placebo

    6 weeks treatment during crossover

    Drug: Placebo

Interventions

  • Active drug will be taken taken orally, QD, either in the morning or in the evening

  • DrugPlacebo

    Will be taken taken orally, QD, either in the morning or in the evening

06

What researchers measure

Primary outcomes

  1. LDL-Cholesterol (mg/dL)

    Change in low density lipoprotein cholesterol (LDL C) following 6 weeks of rosuvastatin 20 mg compared to 6 weeks of placebo treatment

    Time frame: Samples taken on Day 42 (week 6) and on day 84 (week 12)

  2. LDL-Cholesterol (mmol/L)

    Change in low density lipoprotein cholesterol (LDL C) following 6 weeks of rosuvastatin 20 mg compared to 6 weeks of placebo treatment

    Time frame: Samples taken on Day 42 (week 6) and on day 84 (week 12)

Secondary outcomes

  1. TC (mg/dL)

    Efficacy in terms of total cholesterol (TC)

    Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)

  2. TC (mmol/L)

    Efficacy in terms of total cholesterol (TC)

    Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)

  3. Non-HDL C (mg/dL)

    Efficacy in terms of non-high density lipoprotein cholesterol (non-HDL C)

    Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)

  4. Non-HDL C (mmol/L)

    Efficacy in terms of non-high density lipoprotein cholesterol (non-HDL C)

    Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)

  5. ApoB (mg/dL)

    Efficacy in terms of apolipoprotein B (ApoB)

    Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)

  6. ApoB (g/L)

    Efficacy in terms of apolipoprotein B (ApoB)

    Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)

  7. HDL-C (mg/dL)

    Efficacy in terms of high density lipoprotein cholesterol (HDL C)

    Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)

  8. HDL-C (mmol/L)

    Efficacy in terms of high density lipoprotein cholesterol (HDL C)

    Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)

  9. LDL-C, Not on Apheresis (mg/dL)

    Efficacy in terms of low density lipoprotein cholesterol (LDL C) following 6 weeks rosuvastatin 20 mg or placebo treatment in patients not treated with Apheresis

    Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)

  10. LDL-C, Not on Apheresis (mmol/L)

    Efficacy in terms of low density lipoprotein cholesterol (LDL C) following 6 weeks rosuvastatin 20 mg or placebo treatment in patients not treated with Apheresis

    Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)

  11. LDL-C From End of Placebo (mg/dL)

    Change in low density lipoprotein cholesterol (LDL C) from end of placebo period to 6, 12, and 18 weeks of therapy with rosuvastatin 20 mg

    Time frame: Samples taken at Day 42 (week 6), Day 84 (week 12), Day 126 (week 18) and Day 168 (week 24)

  12. LDL-C From End of Placebo (mmol/L)

    Change in low density lipoprotein cholesterol (LDL C) from end of placebo period to 6, 12, and 18 weeks of therapy with rosuvastatin 20 mg

    Time frame: Samples taken at Day 42 (week 6), Day 84 (week 12), Day 126 (week 18) and Day 168 (week 24)

  13. Trough Concentrations

    Pharmacokinetic profile in terms of trough concentrations. Cross-over phase results based on measurements taken after 6 weeks active treatment (rosuvastatin) in the cross-over phase. Maintenance phase results based on measurements taken after 6 weeks active treatment (rosuvastatin) in the maintenance phase.

    Time frame: Samples taken 24 hours post-dose at Day 42 (week 6), Day 84 (week 12), Day 126 (week 18)

  14. Adverse Events

    Safety and tolerability will be described in terms of frequency and severity of adverse events

    Time frame: From screening (5-6weeks before dose) up to the last visit Day 168 (approximately 30 weeks after screening)

  15. AE's Leading to Discontinuation

    Safety and tolerability will be described in terms of rate of discontinuations due to adverse events

    Time frame: From screening (5-6weeks before dose) up to the last visit Day 168 (approximately 30 weeks after screening)

  16. Abnormal Serum Levels

    Safety and tolerability will be described in terms of abnormal serum laboratory values. The reported parameters are not the only ones measured, but rather those for which abnormailities were found

    Time frame: From screening (5-6weeks before dose) up to the last visit Day 168 (approximately 30 weeks after screening)

  17. Height

    Safety and tolerability will be described in terms of growth, including height (linear growth \[cm and standard deviation (SD) score\]), and weight.

    Time frame: Week 0 (start of cross-over), weeks 6, week 12 and week 18

  18. Height Z-score

    Safety and tolerability will be described in terms of growth, including height (linear growth \[cm and standard deviation (SD) score\]), and weight.

    Time frame: Week 0 (start of cross-over), weeks 6, week 12 and week 18

  19. Weight

    Safety and tolerability will be described in terms of growth, including height (linear growth \[cm and standard deviation (SD) score\]), and weight.

    Time frame: Week 0 (start of cross-over), weeks 6, week 12 and week 18

  20. Tanner Stage

    Stages for fem (Pubic hair, Breasts): 1. (Preadol,Preadol) 2. (Sparse, lightly pigmented, medial border of labia,Breast and papilla elevated as small mound; areolar diam incr) 3. (Darker, beginning to curl, incr amount, Breast and areola enlarged, no contour separation) 4. (Course, curly, abundant but less amount in adult,Areola and papilla form secondary mound) 5. (Adult fem triangle, spread to medial surface of thighs,Mature, nipple projects, areola part of general breast contour) For males (Pubic hair, Penis, Testes) 1=(None,Preadol,Preadol) 2=(Scanty, long, light pigm,Slight enl,Enl scrotum, pink texture alt) 3=(Darker, starts to curl, small amount,Longer,Larger) 4=(Resembles adult type, but less in quant; course, curly,Larger; glans and breadth increased in size,Larger, scrotum dark) 5=(Adult distr, spread to medial thighs,Adult size,Adult size). Progr at a normal rate is preferred. Regr is not preferred.

    Time frame: Week 0 (start of cross-over)

  21. TG (mg/dL)

    Efficacy in terms of triglycerides (TG)

    Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)

  22. TG (mmol/L)

    Efficacy in terms of triglycerides (TG)

    Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)

  23. LDL C/HDL C

    Efficacy in terms of low density lipoprotein cholesterol (LDL C) / high density lipoprotein cholesterol (HDL C)

    Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)

  24. TC/HDL C

    Efficacy in terms of total cholesterol (TC) / high density lipoprotein cholesterol (HDL C)

    Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)

  25. Non-HDL C/HDL C

    Efficacy in terms of non-high density lipoprotein cholesterol (non-HDL C) / HDL C

    Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)

  26. ApoB/ApoA

    Efficacy in terms of apolipoprotein B (ApoB) / apolipoprotein A (ApoA)

    Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)

  27. Urinalysis Abnormalitites

    Safety and tolerability will be described in terms of abnormal urine laboratory values

    Time frame: Week 0, week 6, week 12 and week 18

  28. ECG Abnormalities

    Safety and tolerability will be described in terms of abnormal electro cardio gram (ECG)

    Time frame: Week 0

  29. Physical Exam Abnormalitites

    Safety and tolerability will be described in terms of abnormal physical examinations. Only parameters for which abnormalities were found are reported.

    Time frame: Screening, Week 0, week 6, week 12 and week 18, week 24

  30. Abnormal Vital Signs

    Safety and tolerability will be described in terms of abnormal vital signs

    Time frame: From screening (5-6weeks before dose) up to the last visit Day 168 (approximately 30 weeks after screening)

07

Results

Posted Jul 4, 2016

Participant flow

Twenty HoFH patients were recruited to 9 centers within 8 countries (Belgium, Canada, Denmark, Israel, Malaysia, Sweden, Taiwan, and The Netherlands) that participated in the study. FSI date: 03-Nov-2014

Lead-in Phase
Participant flow — Lead-in Phase
MilestoneOverallRosuva First Then PlaceboPlacebo First Then Rosuva
Started1100
Completed1000
Not completed100
Withdrew: Protocol violation100
Cross-Over: First Intervention (6 Weeks)
Participant flow — Cross-Over: First Intervention (6 Weeks)
MilestoneOverallRosuva First Then PlaceboPlacebo First Then Rosuva
Started077
Completed067
Not completed010
Withdrew: No possibility to draw blood010
Cross-Over: Second Interv. (6 Weeks)
Participant flow — Cross-Over: Second Interv. (6 Weeks)
MilestoneOverallRosuva First Then PlaceboPlacebo First Then Rosuva
Started067
Completed067
Not completed000
Maintenance Phase (12 Weeks)
Participant flow — Maintenance Phase (12 Weeks)
MilestoneOverallRosuva First Then PlaceboPlacebo First Then Rosuva
Started1300
Completed1300
Not completed000

Outcome measures

PrimaryLDL-Cholesterol (mg/dL)

Change in low density lipoprotein cholesterol (LDL C) following 6 weeks of rosuvastatin 20 mg compared to 6 weeks of placebo treatment

Time frame:
Samples taken on Day 42 (week 6) and on day 84 (week 12)
Reported as:
Mean · mg/dL
LDL-Cholesterol (mg/dL)
mg/dLC-FAS RosuvastatinC-FAS Placebo
LDL-Cholesterol (mg/dL)396.0 ± 195.99481.4 ± 184.90
Statistical analysis
  • C-FAS Rosuvastatin vs C-FAS Placebo · Mixed Models Analysis · p = 0.005 (statistical significance set at 0.05) · Relative difference in geometric lsm: -22.3 · 95% CI -33.5 to -9.1Rosuvastatin treatment gives on average a 22.3% lower geometric LS mean than placebo.
PrimaryLDL-Cholesterol (mmol/L)

Change in low density lipoprotein cholesterol (LDL C) following 6 weeks of rosuvastatin 20 mg compared to 6 weeks of placebo treatment

Time frame:
Samples taken on Day 42 (week 6) and on day 84 (week 12)
Reported as:
Mean · mmol/L
LDL-Cholesterol (mmol/L)
mmol/LC-FAS RosuvastatinC-FAS Placebo
LDL-Cholesterol (mmol/L)10.26 ± 5.07612.47 ± 4.790
Statistical analysis
  • C-FAS Rosuvastatin vs C-FAS Placebo · Mixed Models Analysis · p = 0.005 (statistical significance set at 0.05) · Relative difference in geometric lsm: -22.3 · 95% CI -33.5 to -9.1Rosuvastatin treatment gives on average a 22.3% lower geometric LS mean than placebo.
SecondaryTC (mg/dL)

Efficacy in terms of total cholesterol (TC)

Time frame:
Samples taken at Day 42 (week 6) and Day 84 (week 12)
Reported as:
Mean · mg/dL
TC (mg/dL)
mg/dLC-FAS RosuvastatinC-FAS Placebo
TC (mg/dL)447.6 ± 195.46539.0 ± 184.91
Statistical analysis
  • C-FAS Rosuvastatin vs C-FAS Placebo · Mixed Models Analysis · p = 0.003 (statistical significance set at 0.05) · Relative difference in geometric lsm: -20.1 · 95% CI -29.7 to -9.1
SecondaryTC (mmol/L)

Efficacy in terms of total cholesterol (TC)

Time frame:
Samples taken at Day 42 (week 6) and Day 84 (week 12)
Reported as:
Mean · mmol/L
TC (mmol/L)
mmol/LC-FAS RosuvastatinC-FAS Placebo
TC (mmol/L)11.59 ± 5.06313.96 ± 4.790
Statistical analysis
  • C-FAS Rosuvastatin vs C-FAS Placebo · Mixed Models Analysis · p = 0.003 (statistical significance set at 0.05) · Relative difference in geometric lsm: -20.1 · 95% CI -29.7 to -9.1
SecondaryNon-HDL C (mg/dL)

Efficacy in terms of non-high density lipoprotein cholesterol (non-HDL C)

Time frame:
Samples taken at Day 42 (week 6) and Day 84 (week 12)
Reported as:
Mean · mg/dL
Non-HDL C (mg/dL)
mg/dLC-FAS RosuvastatinC-FAS Placebo
Non-HDL C (mg/dL)412.1 ± 198.62505.3 ± 186.39
Statistical analysis
  • C-FAS Rosuvastatin vs C-FAS Placebo · Mixed Models Analysis · p = 0.003 (statistical significance set at 0.05) · Relative difference in geometric lsm: -22.9 · 95% CI -33.7 to -10.3
SecondaryNon-HDL C (mmol/L)

Efficacy in terms of non-high density lipoprotein cholesterol (non-HDL C)

Time frame:
Samples taken at Day 42 (week 6) and Day 84 (week 12)
Reported as:
Mean · mmol/L
Non-HDL C (mmol/L)
mmol/LC-FAS RosuvastatinC-FAS Placebo
Non-HDL C (mmol/L)10.67 ± 5.14413.09 ± 4.826
Statistical analysis
  • C-FAS Rosuvastatin vs C-FAS Placebo · Mixed Models Analysis · p = 0.003 (statistical significance set at 0.05) · Relative difference in geometric lsm: -22.9 · 95% CI -33.7 to -10.3
SecondaryApoB (mg/dL)

Efficacy in terms of apolipoprotein B (ApoB)

Time frame:
Samples taken at Day 42 (week 6) and Day 84 (week 12)
Reported as:
Mean · mg/dL
ApoB (mg/dL)
mg/dLC-FAS RosuvastatinC-FAS Placebo
ApoB (mg/dL)234.9 ± 107.02267.9 ± 86.33
Statistical analysis
  • C-FAS Rosuvastatin vs C-FAS Placebo · Mixed Models Analysis · p = 0.024 (statistical significance set at 0.05) · Relative difference in geometric lsm: -17.1 · 95% CI -29.2 to -2.9
SecondaryApoB (g/L)

Efficacy in terms of apolipoprotein B (ApoB)

Time frame:
Samples taken at Day 42 (week 6) and Day 84 (week 12)
Reported as:
Mean · g/L
ApoB (g/L)
g/LC-FAS RosuvastatinC-FAS Placebo
ApoB (g/L)2.35 ± 1.0702.68 ± 0.863
Statistical analysis
  • C-FAS Rosuvastatin vs C-FAS Placebo · Mixed Models Analysis · p = 0.024 (statistical significance set at 0.05) · Relative difference in geometric lsm: -17.1 · 95% CI -29.2 to -2.9
SecondaryHDL-C (mg/dL)

Efficacy in terms of high density lipoprotein cholesterol (HDL C)

Time frame:
Samples taken at Day 42 (week 6) and Day 84 (week 12)
Reported as:
Mean · mg/dL
HDL-C (mg/dL)
mg/dLC-FAS RosuvastatinC-FAS Placebo
HDL-C (mg/dL)35.5 ± 7.2933.7 ± 8.47
Statistical analysis
  • C-FAS Rosuvastatin vs C-FAS Placebo · Mixed Models Analysis · p = 0.314 (statistical significance set at 0.05) · Relative difference in geometric lsm: 7.4 · 95% CI -7.4 to 24.5
SecondaryHDL-C (mmol/L)

Efficacy in terms of high density lipoprotein cholesterol (HDL C)

Time frame:
Samples taken at Day 42 (week 6) and Day 84 (week 12)
Reported as:
Mean · mmol/L
HDL-C (mmol/L)
mmol/LC-FAS RosuvastatinC-FAS Placebo
HDL-C (mmol/L)0.92 ± 0.1890.87 ± 0.218
Statistical analysis
  • C-FAS Rosuvastatin vs C-FAS Placebo · Mixed Models Analysis · p = 0.314 (statistical significance set at 0.05) · Relative difference in geometric lsm: 7.4 · 95% CI -7.4 to 24.5
SecondaryLDL-C, Not on Apheresis (mg/dL)

Efficacy in terms of low density lipoprotein cholesterol (LDL C) following 6 weeks rosuvastatin 20 mg or placebo treatment in patients not treated with Apheresis

Time frame:
Samples taken at Day 42 (week 6) and Day 84 (week 12)
Reported as:
Mean · mg/dL
LDL-C, Not on Apheresis (mg/dL)
mg/dLC-FAS RosuvastatinC-FAS Placebo
LDL-C, Not on Apheresis (mg/dL)479.8 ± 239.07594.7 ± 203.60
Statistical analysis
  • C-FAS Rosuvastatin · Mixed Models Analysis · p = 0.080 (statistical significance set at 0.05) · Relative difference in geometric lsm: -26.3 · 95% CI -48.7 to 6.0
SecondaryLDL-C, Not on Apheresis (mmol/L)

Efficacy in terms of low density lipoprotein cholesterol (LDL C) following 6 weeks rosuvastatin 20 mg or placebo treatment in patients not treated with Apheresis

Time frame:
Samples taken at Day 42 (week 6) and Day 84 (week 12)
Reported as:
Mean · mmol/L
LDL-C, Not on Apheresis (mmol/L)
mmol/LC-FAS RosuvastatinC-FAS Placebo Not on Apheresis
LDL-C, Not on Apheresis (mmol/L)12.43 ± 6.19115.40 ± 5.274
Statistical analysis
  • C-FAS Rosuvastatin · Mixed Models Analysis · p = 0.080 (statistical significance set at 0.05) · Relative difference in geometric lsm: -26.3 · 95% CI -48.7 to 6.0
SecondaryLDL-C From End of Placebo (mg/dL)

Change in low density lipoprotein cholesterol (LDL C) from end of placebo period to 6, 12, and 18 weeks of therapy with rosuvastatin 20 mg

Time frame:
Samples taken at Day 42 (week 6), Day 84 (week 12), Day 126 (week 18) and Day 168 (week 24)
Reported as:
Mean · mg/dL
LDL-C From End of Placebo (mg/dL)
mg/dLM-FAS RosuvastatinM-FAS Placebo
End of Placebo472.9 ± 171.77491.3 ± 215.46
6 weeks after end of Placebo399.4 ± 214.28421.7 ± 224.49
12 weeks after end of Placebo345.8 ± 214.69394.7 ± 178.45
18 weeks after end of PlaceboNA ± NA441.8 ± 260.31
SecondaryLDL-C From End of Placebo (mmol/L)

Change in low density lipoprotein cholesterol (LDL C) from end of placebo period to 6, 12, and 18 weeks of therapy with rosuvastatin 20 mg

Time frame:
Samples taken at Day 42 (week 6), Day 84 (week 12), Day 126 (week 18) and Day 168 (week 24)
Reported as:
Mean · mmol/L
LDL-C From End of Placebo (mmol/L)
mmol/LM-FAS RosuvastatinM-FAS Placebo
End of Placebo12.25 ± 4.44912.73 ± 5.583
6 weeks after end of Placebo10.34 ± 5.55110.92 ± 5.813
12 weeks after end of Placebo8.96 ± 5.55810.22 ± 4.621
18 weeks after end of PlaceboNA ± NA11.44 ± 6.740
SecondaryTrough Concentrations

Pharmacokinetic profile in terms of trough concentrations. Cross-over phase results based on measurements taken after 6 weeks active treatment (rosuvastatin) in the cross-over phase. Maintenance phase results based on measurements taken after 6 weeks active treatment (rosuvastatin) in the maintenance phase.

Time frame:
Samples taken 24 hours post-dose at Day 42 (week 6), Day 84 (week 12), Day 126 (week 18)
Reported as:
Mean · ng/mL
Trough Concentrations
ng/mLCross-over PhaseMaintenance Phase
Trough Concentrations7.387 ± 8.114.482 ± 3.50
SecondaryAdverse Events

Safety and tolerability will be described in terms of frequency and severity of adverse events

Time frame:
From screening (5-6weeks before dose) up to the last visit Day 168 (approximately 30 weeks after screening)
Reported as:
Number · adverse events
Adverse Events
adverse eventsLead-inCross-over PhaseMaintenance
Any AE451
Any TEAE451
Any AE leading to death000
Any SAE000
SecondaryAE's Leading to Discontinuation

Safety and tolerability will be described in terms of rate of discontinuations due to adverse events

Time frame:
From screening (5-6weeks before dose) up to the last visit Day 168 (approximately 30 weeks after screening)
Reported as:
Number · adverse events
AE's Leading to Discontinuation
adverse eventsLead-inCross-over PhaseMaintenance Phase
AE's Leading to Discontinuation000
SecondaryAbnormal Serum Levels

Safety and tolerability will be described in terms of abnormal serum laboratory values. The reported parameters are not the only ones measured, but rather those for which abnormailities were found

Time frame:
From screening (5-6weeks before dose) up to the last visit Day 168 (approximately 30 weeks after screening)
Reported as:
Number · participants
Abnormal Serum Levels
participantsRos/Pla <LLNRos/Pla >ULNPla/Ros <LLNPla/Ros >ULN
Alanine Aminotransferase week 00000
Alanine Aminotransferase week 60100
Alanine Aminotransferase week 120001
Alanine Aminotransferase week 180001
Alanine Aminotransferase week 240100
Albumin week 00001
Albumin week 60000
Albumin week 120000
Albumin week 180001
Albumin week 240000
Bicarbonate week 01001
Bicarbonate week 60010
Bicarbonate week 121010
Bicarbonate week 180010
Bicarbonate week 241010
Blood Urea Nitrogen week 01000
Blood Urea Nitrogen week 61000
Blood Urea Nitrogen week 121000
Blood Urea Nitrogen week 181000
Blood Urea Nitrogen week 240000
Chloride week 00201
Chloride week 60001
Chloride week 120000
Chloride week 180101
Chloride week 240000
Creatine Kinase week 00000
Creatine Kinase week 60100
Creatine Kinase week 120000
Creatine Kinase week 180000
Creatine Kinase week 240100
Glucose week 00100
Glucose week 60001
Glucose week 120000
Glucose week 180101
Glucose week 240000
Potassium week 00001
Potassium week 60000
Potassium week 120000
Potassium week 180000
Potassium week 240000
Protein week 00000
Protein week 60000
Protein week 120001
Protein week 180000
Protein week 240001
Sodium week 02000
Sodium week 61000
Sodium week 120000
Sodium week 183010
Sodium week 240020
Total Bilirubin week 00000
Total Bilirubin week 60100
Total Bilirubin week 120000
Total Bilirubin week 180000
Total Bilirubin week 240000
Urate week 00100
Urate week 60101
Urate week 120100
Urate week 180101
Urate week 240101
Ery. Mean Corpuscular HGB Concentration week 02030
Ery. Mean Corpuscular HGB Concentration week 60020
Ery. Mean Corpuscular HGB Concentration week 123020
Ery. Mean Corpuscular HGB Concentration week 181020
Ery. Mean Corpuscular HGB Concentration week 242030
Ery. Mean Corpuscular Hemoglobin week 01030
Ery. Mean Corpuscular Hemoglobin week 61020
Ery. Mean Corpuscular Hemoglobin week 122020
Ery. Mean Corpuscular Hemoglobin week 181020
Ery. Mean Corpuscular Hemoglobin week 241020
Ery. Mean Corpuscular Volume week 01020
Ery. Mean Corpuscular Volume week 61020
Ery. Mean Corpuscular Volume week 121020
Ery. Mean Corpuscular Volume week 181020
Ery. Mean Corpuscular Volume week 241020
Erythrocytes week 01001
Erythrocytes week 60000
Erythrocytes week 120011
Erythrocytes week 180010
Erythrocytes week 240202
Hematocrit week 02020
Hematocrit week 62030
Hematocrit week 121020
Hematocrit week 181030
Hematocrit week 240010
Hemoglobin week 02030
Hemoglobin week 62030
Hemoglobin week 121030
Hemoglobin week 181030
Hemoglobin week 240020
Lymphocytes/Leukocytes week 00001
Lymphocytes/Leukocytes week 60001
Lymphocytes/Leukocytes week 120001
Lymphocytes/Leukocytes week 180101
Lymphocytes/Leukocytes week 240101
Neutrophils, Segmented/Leukocytes week 00000
Neutrophils, Segmented/Leukocytes week 60000
Neutrophils, Segmented/Leukocytes week 120000
Neutrophils, Segmented/Leukocytes week 181000
Neutrophils, Segmented/Leukocytes week 241000
Neutrophils/Leukocytes week 00000
Neutrophils/Leukocytes week 61000
Neutrophils/Leukocytes week 120000
Neutrophils/Leukocytes week 180000
Neutrophils/Leukocytes week 240000
Platelets week 00100
Platelets week 60001
Platelets week 120000
Platelets week 180000
Platelets week 240001
SecondaryHeight

Safety and tolerability will be described in terms of growth, including height (linear growth \[cm and standard deviation (SD) score\]), and weight.

Time frame:
Week 0 (start of cross-over), weeks 6, week 12 and week 18
Reported as:
Mean · cm
Height
cmRos/PlaPla/Ros
Height (cm) week 0144.0 ± 17.82140.9 ± 15.70
Height (cm) week 6144.9 ± 17.70141.1 ± 16.11
Height (cm) week 12145.7 ± 18.07142.0 ± 17.17
Height (cm) week 18146.9 ± 17.68142.3 ± 16.99
Height (cm) week 24147.1 ± 17.94143.5 ± 17.58
SecondaryHeight Z-score

Safety and tolerability will be described in terms of growth, including height (linear growth \[cm and standard deviation (SD) score\]), and weight.

Time frame:
Week 0 (start of cross-over), weeks 6, week 12 and week 18
Reported as:
Mean · ratio
Height Z-score
ratioRos/PlaPla/Ros
Height z-score week 0-0.42 ± 1.697-0.75 ± 1.555
Height z-score week 6-0.29 ± 1.703-0.71 ± 1.644
Height z-score week 12-0.18 ± 1.742-0.70 ± 1.776
Height z-score week 180.00 ± 1.721-0.65 ± 1.757
Height z-score week 240.04 ± 1.752-0.49 ± 1.758
SecondaryWeight

Safety and tolerability will be described in terms of growth, including height (linear growth \[cm and standard deviation (SD) score\]), and weight.

Time frame:
Week 0 (start of cross-over), weeks 6, week 12 and week 18
Reported as:
Mean · kg
Weight
kgRos/PlaPla/Ros
Weight (kg) week 037.39 ± 12.73140.19 ± 16.520
Weight (kg) week 638.14 ± 13.57740.36 ± 16.462
Weight (kg) week 1238.63 ± 14.42642.30 ± 18.651
Weight (kg) week 1839.31 ± 14.58842.50 ± 17.990
Weight (kg) week 2439.90 ± 14.55043.00 ± 17.867
SecondaryTanner Stage

Stages for fem (Pubic hair, Breasts): 1. (Preadol,Preadol) 2. (Sparse, lightly pigmented, medial border of labia,Breast and papilla elevated as small mound; areolar diam incr) 3. (Darker, beginning to curl, incr amount, Breast and areola enlarged, no contour separation) 4. (Course, curly, abundant but less amount in adult,Areola and papilla form secondary mound) 5. (Adult fem triangle, spread to medial surface of thighs,Mature, nipple projects, areola part of general breast contour) For males (Pubic hair, Penis, Testes) 1=(None,Preadol,Preadol) 2=(Scanty, long, light pigm,Slight enl,Enl scrotum, pink texture alt) 3=(Darker, starts to curl, small amount,Longer,Larger) 4=(Resembles adult type, but less in quant; course, curly,Larger; glans and breadth increased in size,Larger, scrotum dark) 5=(Adult distr, spread to medial thighs,Adult size,Adult size). Progr at a normal rate is preferred. Regr is not preferred.

Time frame:
Week 0 (start of cross-over)
Reported as:
Mean · stage
Tanner Stage
stageRos/PlaPla/Ros
Tanner stage week 02.0 ± 1.411.7 ± 1.11
Tanner stage week 242.3 ± 1.382.0 ± 0.2
SecondaryTG (mg/dL)

Efficacy in terms of triglycerides (TG)

Time frame:
Samples taken at Day 42 (week 6) and Day 84 (week 12)
Reported as:
Mean · mg/dL
TG (mg/dL)
mg/dLC-FAS RosuvastatinC-FAS Placebo
TG (mg/dL)79.8 ± 24.48119.5 ± 52.67
Statistical analysis
  • C-FAS Rosuvastatin vs C-FAS Placebo · Mixed Models Analysis · p = 0.004 (statistical significance set at 0.05) · Relative difference in geometric lsm: -30.4 · 95% CI -44.2 to -13.3
SecondaryTG (mmol/L)

Efficacy in terms of triglycerides (TG)

Time frame:
Samples taken at Day 42 (week 6) and Day 84 (week 12)
Reported as:
Mean · mmol/L
TG (mmol/L)
mmol/LC-FAS RosuvastatinC-FAS Placebo
TG (mmol/L)0.90 ± 0.2771.35 ± 0.595
Statistical analysis
  • C-FAS Rosuvastatin vs C-FAS Placebo · Mixed Models Analysis · p = 0.004 (statistical significance set at 0.05) · Relative difference in geometric lsm: -30.4 · 95% CI -44.2 to -13.3
SecondaryLDL C/HDL C

Efficacy in terms of low density lipoprotein cholesterol (LDL C) / high density lipoprotein cholesterol (HDL C)

Time frame:
Samples taken at Day 42 (week 6) and Day 84 (week 12)
Reported as:
Mean · ratio
LDL C/HDL C
ratioC-FAS RosuvastatinC-FAS Placebo
LDL C/HDL C12.208 ± 7.863815.600 ± 9.1317
Statistical analysis
  • C-FAS Rosuvastatin vs C-FAS Placebo · Mixed Models Analysis · p = 0.006 (statistical significance set at 0.05) · Relative difference in geometric lsm: -27.6 · 95% CI -41.2 to -11.0
SecondaryTC/HDL C

Efficacy in terms of total cholesterol (TC) / high density lipoprotein cholesterol (HDL C)

Time frame:
Samples taken at Day 42 (week 6) and Day 84 (week 12)
Reported as:
Mean · ratio
TC/HDL C
ratioC-FAS RosuvastatinC-FAS Placebo
TC/HDL C13.704 ± 8.041417.416 ± 9.5454
Statistical analysis
  • C-FAS Rosuvastatin vs C-FAS Placebo · Mixed Models Analysis · p = 0.005 (statistical significance set at 0.05) · Relative difference in geometric lsm: -25.6 · 95% CI -38.1 to -10.5
SecondaryNon-HDL C/HDL C

Efficacy in terms of non-high density lipoprotein cholesterol (non-HDL C) / HDL C

Time frame:
Samples taken at Day 42 (week 6) and Day 84 (week 12)
Reported as:
Mean · ratio
Non-HDL C/HDL C
ratioC-FAS RosuvastatinC-FAS Placebo
Non-HDL C/HDL C12.704 ± 8.041416.416 ± 9.5454
Statistical analysis
  • C-FAS Rosuvastatin · Mixed Models Analysis · p = 0.005 (statistical significance set at 0.05) · Relative difference in geometric lsm: -28.2 · 95% CI -41.7 to -11.4
SecondaryApoB/ApoA

Efficacy in terms of apolipoprotein B (ApoB) / apolipoprotein A (ApoA)

Time frame:
Samples taken at Day 42 (week 6) and Day 84 (week 12)
Reported as:
Mean · ratio
ApoB/ApoA
ratioC-FAS RosuvastatinC-FAS Placebo
ApoB/ApoA2.408 ± 1.32592.873 ± 1.4669
Statistical analysis
  • C-FAS Rosuvastatin · Mixed Models Analysis · p = 0.013 (statistical significance set at 0.05) · Relative difference in geometric lsm: -20.4 · 95% CI -32.8 to -5.6
SecondaryUrinalysis Abnormalitites

Safety and tolerability will be described in terms of abnormal urine laboratory values

Time frame:
Week 0, week 6, week 12 and week 18
Reported as:
Number · participants
Urinalysis Abnormalitites
participantsRos/PlaPla/Ros
Urine Protein week 032
Urine Protein week 612
Urine Protein week 1232
Urine Protein week 1821
Urine Protein week 2421
Urine Ketones week 010
Urine Ketones week 600
Urine Ketones week 1200
Urine Ketones week 1801
Urine Ketones week 2400
Urine Blood week 012
Urine Blood week 621
Urine Blood week 1212
Urine Blood week 1811
Urine Blood week 2411
SecondaryECG Abnormalities

Safety and tolerability will be described in terms of abnormal electro cardio gram (ECG)

Time frame:
Week 0
Reported as:
Number · participants
ECG Abnormalities
participantsSafety Analysis SetC-FAS RosuvastatinC-FAS Placebo
ECG Abnormalities000
SecondaryPhysical Exam Abnormalitites

Safety and tolerability will be described in terms of abnormal physical examinations. Only parameters for which abnormalities were found are reported.

Time frame:
Screening, Week 0, week 6, week 12 and week 18, week 24
Reported as:
Number · participants
Physical Exam Abnormalitites
participantsRos/PlaPla/Ros
General Appearance screening12
General Appearance week 012
General Appearance week 612
General Appearance week 1212
General Appearance week 1812
General Appearance week 2412
Head and Neck screening02
Head and Neck week 002
Head and Neck week 602
Head and Neck week 1202
Head and Neck week 1802
Head and Neck week 2401
Lymph Nodes screening00
Lymph Nodes week 001
Lymph Nodes week 600
Lymph Nodes week 1200
Lymph Nodes week 1800
Lymph Nodes week 2400
Skin screening52
Skin week 052
Skin week 652
Skin week 1252
Skin week 1852
Skin week 2452
SecondaryAbnormal Vital Signs

Safety and tolerability will be described in terms of abnormal vital signs

Time frame:
From screening (5-6weeks before dose) up to the last visit Day 168 (approximately 30 weeks after screening)
Reported as:
Number · participants
Abnormal Vital Signs
participantsSafety Analysis Set
Abnormal Vital Signs0

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lead-in—0/11 (0%)4/11 (36.4%)
Cross-over—0/14 (0%)4/14 (28.6%)
Maintenance—0/13 (0%)1/13 (7.7%)
Most frequent other events
Most frequent other events
EventLead-inCross-overMaintenance
Influenza like illnessGeneral disorders2/112/140/13
Peripheral swellingGeneral disorders1/110/140/13
Abdominal pain upperGastrointestinal disorders1/110/140/13
Blood bicarbonate decreasedInvestigations0/110/141/13
InfluenzaInfections and infestations0/111/140/13
NasopharyngitisInfections and infestations0/111/140/13
Chest painGeneral disorders0/111/140/13

Baseline characteristics

Number of baseline participants are not the same as started as there was a lead-in phase in between and as 6 of the 20 patients starting did not enter the cross-over phase, the beginning of which defines the baseline.

Age, Continuous
Age, Continuous(Years)Cross-over
Mean10.9 ± 2.70
Sex: Female, Male
Sex: Female, Male(Participants)Cross-over
Female7
Male7
08

Study locations

9 sites
  • Research Site
    Brussels (Woluwé-St-Lambert), Belgium
  • Research Site
    Chicoutimi, Quebec, Canada
  • Research Site
    København Ø, Denmark
  • Research Site
    Haifa, Israel
  • Research Site
    Kuala Lumpur, Malaysia
  • Research Site
    Kubang Kerian, Malaysia
  • Research Site
    Amsterdam, Netherlands
  • Research Site
    Goteborg, Netherlands
  • Research Site
    Taipei, Taiwan
09

References and documents

Publications

  • Stein EA, Dann EJ, Wiegman A, Skovby F, Gaudet D, Sokal E, Charng MJ, Mohamed M, Luirink I, Raichlen JS, Sunden M, Carlsson SC, Raal FJ, Kastelein JJP. Efficacy of Rosuvastatin in Children With Homozygous Familial Hypercholesterolemia and Association With Underlying Genetic Mutations. J Am Coll Cardiol. 2017 Aug 29;70(9):1162-1170. doi: 10.1016/j.jacc.2017.06.058. PubMed 28838366 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2014, a primary completion of Jul 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2016, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2014
First posted
Aug 27, 2014
Start
Nov 2014
Primary completionActual
Jul 2015
CompletionActual
Jul 2015
Results first posted
Jul 4, 2016
Last update
Jul 4, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 4, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02226198
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 27, 2014
Start date
Nov 2014
Primary completion
Jul 2015
Completion
Jul 2015
Results posted
Jul 4, 2016
Last update
Jul 4, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rosuvastatin

Start the discussion